The study aimed to compare the effectiveness of two antihypertensive therapies, spironolactone and eplerenone, in treating patients with essential arterial hypertension and atrial fibrillation.
It involved 99 patients, who were divided into two groups, each receiving one of the therapies for six months, with various health measurements taken to assess their condition.
Results showed that a higher percentage of patients on eplerenone reached target diastolic blood pressure levels compared to those on spironolactone (87.8% vs. 67.5%).